Spots Global Cancer Trial Database for penpulimab
Every month we try and update this database with for penpulimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TACE Combined With Penpulimab and Anlotinib for Advanced HCC | NCT05344924 | Hepatocellular ... | TACE+penpulimab... | 18 Years - 80 Years | Zhongda Hospital | |
| A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | NCT05493995 | Pancreatic Neop... | Penpulimab Anlotinib Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer | NCT05028504 | Gynecological C... | Penpulimab Anlotinib | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer | NCT05576480 | Rectal Cancer Locally Advance... | Short-course ra... Penpulimab CAPEOX TME surgery | 18 Years - 75 Years | Ruijin Hospital | |
| Anlotinib or Penpulimab in Combination With RAI for DTC | NCT04952493 | Thyroid Cancer | Anlotinib hydro... Sodium Iodide I... Penpulimab | 18 Years - | Peking Union Medical College Hospital | |
| Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | NCT05229003 | Metastatic Colo... | Anlotinib Penpulimab Irinotecan | 18 Years - 85 Years | Fudan University | |
| Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | NCT05347641 | Primary Central... | Penpulimab | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | NCT05347641 | Primary Central... | Penpulimab | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Penpulimab in Maintenance Therapy in Lymphoma | NCT05680038 | Lymphoma | Penpulimab | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer | NCT05726175 | Breast Cancer | Disitamab Vedot... Penpulimab | 18 Years - 75 Years | West China Hospital | |
| A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer | NCT05028504 | Gynecological C... | Penpulimab Anlotinib | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer | NCT05028504 | Gynecological C... | Penpulimab Anlotinib | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | NCT04974398 | Nasopharyngeal ... | Penpulimab placebo | 12 Years - 75 Years | Akeso | |
| Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | NCT05229003 | Metastatic Colo... | Anlotinib Penpulimab Irinotecan | 18 Years - 85 Years | Fudan University | |
| Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer | NCT06051851 | Pancreatic Aden... | Penpulimab Anlotinib Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer | NCT05028504 | Gynecological C... | Penpulimab Anlotinib | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma | NCT05494060 | Carcinoma Gastrointestina... Stomach Cancer Gastroesophagea... Digestive Syste... Gastric Cancer Gastrointestina... | Anlotinib hydro... Penpulimab Inje... XELOX | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | NCT04974398 | Nasopharyngeal ... | Penpulimab placebo | 12 Years - 75 Years | Akeso | |
| The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment | NCT05885399 | Pheochromocytom... Pheochromocytom... Paraganglioma, ... | Penpulimab | 15 Years - 75 Years | Peking Union Medical College Hospital | |
| A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma | NCT05244642 | Hodgkin Disease... | Penpulimab Investigator's ... | 18 Years - | Akeso | |
| The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment | NCT05885399 | Pheochromocytom... Pheochromocytom... Paraganglioma, ... | Penpulimab | 15 Years - 75 Years | Peking Union Medical College Hospital | |
| A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody | NCT06048315 | Lung Cancer TKI Resistance EGFR Sensitive ... Anlotinib Pianzumab | Anlotinib Penpulimab | 18 Years - 75 Years | Qianfoshan Hospital | |
| A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | NCT05493995 | Pancreatic Neop... | Penpulimab Anlotinib Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer | NCT05726175 | Breast Cancer | Disitamab Vedot... Penpulimab | 18 Years - 75 Years | West China Hospital | |
| TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. | NCT06297642 | Advanced Malign... | TQB2928 injecti... Penpulimab | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib or Penpulimab in Combination With RAI for DTC | NCT04952493 | Thyroid Cancer | Anlotinib hydro... Sodium Iodide I... Penpulimab | 18 Years - | Peking Union Medical College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
